-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Supporting Precision Oncology
Targeted therapies, immuno-oncology, and predictive biomarker-based medicines
Aug 11, 2020
About the Report
Precision oncology offers to transform cancer care with medicines tailored to each patient by targeting specific bioprocesses, genetic mutations, or by precisely enhancing the individual’s immune system. Within this report, the current use of personalized and precision cancer medicines, associated biomarkers, the pipeline of emerging therapies and development trends are discussed, along with the range of challenges facing oncologists and other stakeholders as advances in cancer treatment shifts even further away from the systemic chemotherapies of the past. In the era of COVID-19, the FDA remains committed to expedited review for oncology products and has provided guidance to assist sponsors making clinical trial modifications due to impacts from the pandemic to ensure the safety of trial participants. Notably, as of July 7, 13 novel oncology products were approved by the agency in 2020, compared to five products in the same time frame in 2019.
Report Summary
This year’s oncology report examines market trends for targeted and predictive biomarker therapies. The number of oncology products that require or recommend biomarker testing prior to use has nearly doubled since 2015 in the United States. The report also provides insights into clinical applications of biomarkers in routine care and clinical trials. Specifically, the number of clinical trials incorporating pharmacogenomic analysis to stratify patients for predictive response, safety, or dosing, has more than doubled since 2010 and represents 42% of oncology trials in 2019. Finally, the report provides an analysis of the pipeline for immuno-oncology and tissue-agnostic products that finds over 700 immuno-oncology therapies in development from Phase I to pre-registration in 2019 along with over 20 tissue-agnostic therapies.
Key Findings
The number of predictive medicines that require or recommend biomarker testing prior to use has increased steadily in the United States and now represents nearly two-thirds of cancer therapies launched between 2015 and 2019.
U.S. New Active Substances in Oncology by Year of Indication Approval, 2015-2019
- The cancer treatment landscape in the United States has continued to evolve since 2015, with new medicines targeting 24 different cancer types.
- The majority of medicines were targeted therapies, and 58% require or recommend biomarker testing prior to use, to single out which patients are most likely to respond to a treatment based on the molecular fingerprint of their tumor.
- Cancer patients in the United States gain access to novel cancer therapies on average five months earlier than patients in Europe.
- Oncology medicines that first launch in the United States and require biomarker testing prior to use reach Europe almost nine months later, on average.
The number of clinical trials incorporating pharmacogenomic analysis to stratify patients for predictive response, safety, or dosing, has more than doubled since 2010 and represents 42% of oncology trials in 2019.
Number and Percentage of Oncology Trials by Biomarker and Immune-oncology Segmentation, 2010-2019
- oncology, the total number of trials with innovative trial designs, which include adaptative, umbrella, and basket trials, has more than tripled since 2010.
- The utility of novel trial designs supports the clinical development of precision medicines by allowing the testing of multiple agents or investigation of multiple hypotheses within a single trial.
- Despite some challenges, there have been increases in the use of biomarker tests in routine care for certain tumor types across the United States and Europe.
- The current and future use of precision oncology therapies will depend on continued uptake of biomarker testing.
In 2019, there were over 20 tissue-agnostic therapies in development across 28 unique indications.
Tissue-Agnostic Pipeline by Phase, Tumor Type, and Biomarkerm 2019
- Immuno-oncology therapies have made up the bulk of clinical trials in oncology and the emerging oncology pipeline over the past five years.
- The immuno-oncology new product pipeline is robust, with over 700 therapies currently in development across all phases.
- By 2019, the early stage pipeline has started to shift away from checkpoint inhibitors and towards an increasing number of CAR products.
- The number of CAR cell therapy trials has grown 38% since 2015, with the success of CAR T-cell therapy in B-cell cancers spurring development into other hematologic malignancies as well as solid tumors.